VENuS Trial
Cross-source consensus on VENuS Trial from 1 sources and 5 claims.
1 sources · 5 claims
Uses
Risks & contraindications
Other
Highlighted claims
- The trial is designed as a 28-week, two-arm, multicentre randomized controlled trial with extensive blinding. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- The VENuS trial evaluates vunakizumab versus placebo in symptomatic erosive hand osteoarthritis. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- Participants are randomized equally to vunakizumab or placebo, with a 24-week intervention period and primary assessment at 28 weeks. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- The trial plans to enroll 150 participants from seven public tertiary teaching hospitals in China. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial
- The trial’s main limitation is that 28 weeks may be insufficient to fully assess long-term structural progression. — Efficacy of Vunakizumab in Erosive haNd osteoarthritiS (VENuS): protocol for a multicentre, randomised controlled trial